$BIORQ
BIORA THERAPEUTICS, INC. Stock $biorq

$biorq Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000095017024060530 Filed on May 15, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q1
Revenue	$318.0K	$542.0K	$2.000K
YoY Change	15800.0%	27000.0%	-99.85%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$8.400M	$9.053M	$8.356M
YoY Change	-6.18%	8.34%	-37.91%
% of Gross Profit
Research & Development	$7.704M	$7.005M	$7.190M
YoY Change	28.76%	-2.57%	9.64%
% of Gross Profit
Depreciation & Amortization	$100.0K	$105.0K	$100.0K
YoY Change	-50.0%	5.0%	-66.67%
% of Gross Profit
Operating Expenses	$16.10M	$16.06M	$15.55M
YoY Change	7.82%	3.29%	-22.33%
Operating Profit	-$15.79M	-$15.52M	-$15.54M
YoY Change	5.71%	-0.18%	-21.92%
Interest Expense	$711.0K	$2.757M	$2.680M
YoY Change	-73.7%	2.87%	-2.9%
% of Operating Profit
Other Income/Expense, Net	$9.892M	$217.0K	-$81.00K
YoY Change	-197940.0%	-367.9%	-90.01%
Pretax Income	$6.398M	-$4.141M	-$17.44M
YoY Change	-135.94%	-76.26%	20.37%
Income Tax	-$67.00K	$48.00K	$0.00
% Of Pretax Income	-1.05%
Net Earnings	$6.465M	-$4.200M	-$17.40M
YoY Change	-136.31%	-75.86%	26.01%
Net Earnings / Revenue	2033.02%	-774.91%	-870000.0%
Basic Earnings Per Share	$0.18	-$0.14	-$1.59
Diluted Earnings Per Share	-$0.04	-$0.14	-$1.59
COMMON SHARES
Basic Shares Outstanding	35.88M	30.31M	11.83M
Diluted Shares Outstanding	74.22M	29.30M	10.97M

Balance Sheet

Concept	2024 Q2	2024 Q1	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$5.325M	$10.82M	$30.46M
YoY Change	-79.87%	-64.48%	-54.69%
Cash & Equivalents	$5.100M	$10.60M	$30.50M
Short-Term Investments
Other Short-Term Assets	$406.0K	$169.0K	$309.0K
YoY Change	110.36%	-45.31%	-73.06%
Inventory
Prepaid Expenses	$2.648M	$2.260M	$3.059M
Receivables
Other Receivables
Total Short-Term Assets	$9.201M	$14.07M	$37.17M
YoY Change	-72.85%	-62.14%	-50.46%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.268M	$1.136M	$1.498M
YoY Change	-6.14%	-24.17%	-45.37%
Goodwill	$6.072M	$6.072M	$6.072M
YoY Change	0.0%	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments	$0.00	$0.00	$6.000M
YoY Change	-100.0%	-100.0%
Other Assets	$505.0K	$293.0K	$6.259M
YoY Change	-92.2%	-95.32%	1819.94%
Total Long-Term Assets	$9.062M	$8.919M	$16.08M
YoY Change	-42.6%	-44.52%	37.18%
TOTAL ASSETS
Total Short-Term Assets	$9.201M	$14.07M	$37.17M
Total Long-Term Assets	$9.062M	$8.919M	$16.08M
Total Assets	$18.26M	$22.99M	$53.24M
YoY Change	-63.23%	-56.82%	-38.62%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$7.512M	$4.936M	$3.422M
YoY Change	48.99%	44.24%	-36.39%
Accrued Expenses	$15.58M	$14.87M	$16.33M
YoY Change	-26.77%	-8.98%	-43.67%
Deferred Revenue	$32.00K	$0.00	$44.00K
YoY Change	-23.81%	-100.0%	-77.32%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.912M	$1.976M
YoY Change
Total Short-Term Liabilities	$45.99M	$51.10M	$25.08M
YoY Change	22.1%	103.74%	-46.32%
LONG-TERM LIABILITIES
Long-Term Debt	$43.77M	$43.28M	$128.2M
YoY Change	-65.96%	-66.24%	1.14%
Other Long-Term Liabilities	$581.0K	$2.583M	$4.973M
YoY Change	-86.54%	-48.06%	-23.04%
Total Long-Term Liabilities	$581.0K	$2.583M	$4.973M
YoY Change	-86.54%	-48.06%	-23.04%
TOTAL LIABILITIES
Total Short-Term Liabilities	$45.99M	$51.10M	$25.08M
Total Long-Term Liabilities	$581.0K	$2.583M	$4.973M
Total Liabilities	$107.6M	$123.2M	$158.2M
YoY Change	-36.92%	-22.16%	-12.05%
SHAREHOLDERS EQUITY
Retained Earnings	-$948.7M	-$955.1M	-$844.3M
YoY Change	10.05%	13.12%	5.21%
Common Stock	$878.4M	$874.0M	$758.4M
YoY Change	15.54%	15.25%	4.11%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$89.32M	-$100.2M	-$105.0M
YoY Change
Total Liabilities & Shareholders Equity	$18.26M	$22.99M	$53.24M
YoY Change	-63.23%	-56.82%	-38.62%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2023 Q1
OPERATING ACTIVITIES
Net Income	$6.465M	-$4.200M	-$17.40M
YoY Change	-136.31%	-75.86%	26.01%
Depreciation, Depletion And Amortization	$100.0K	$105.0K	$100.0K
YoY Change	-50.0%	5.0%	-66.67%
Cash From Operating Activities	-$10.95M	-$12.50M	-$12.10M
YoY Change	-5.76%	3.31%	-49.58%
INVESTING ACTIVITIES
Capital Expenditures	$180.0K	$15.00K	$16.00K
YoY Change	800.0%	-6.25%	-95.32%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$3.020M	$10.00K
YoY Change	-100.0%	30100.0%
Cash From Investing Activities	-$180.0K	$3.005M	-$6.000K
YoY Change	847.37%	-50183.33%	-98.25%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	5.637M	5.100M	12.08M
YoY Change	-26.12%	-57.78%	285.48%
NET CHANGE
Cash From Operating Activities	-10.95M	-12.50M	-12.10M
Cash From Investing Activities	-180.0K	3.005M	-6.000K
Cash From Financing Activities	5.637M	5.100M	12.08M
Net Change In Cash	-5.495M	-4.391M	-23.00K
YoY Change	37.0%	18991.3%	-99.89%
FREE CASH FLOW
Cash From Operating Activities	-$10.95M	-$12.50M	-$12.10M
Capital Expenditures	$180.0K	$15.00K	$16.00K
Free Cash Flow	-$11.13M	-$12.52M	-$12.12M
YoY Change	-4.38%	3.29%	-50.23%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2024Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001580063
CY2024Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q1	dei	Amendment Flag AmendmentFlag	false
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2024Q1	us-gaap	Operating Lease Liability Statement Of Financial Position Extensible List OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList	http://bioratherapeutics.com/20240331#AccruedExpensesAndOtherLiabilitiesCurrent
CY2024Q1	us-gaap	Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable	2024-04-01
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2024Q1	dei	Document Type DocumentType	10-Q
CY2024Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2024Q1	dei	Document Period End Date DocumentPeriodEndDate	2024-03-31
CY2024Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q1	dei	Entity File Number EntityFileNumber	001-39334
CY2024Q1	dei	Entity Registrant Name EntityRegistrantName	Biora Therapeutics, Inc.
CY2024Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2024Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-3950390
CY2024Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	4330 La Jolla Village Drive
CY2024Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 300
CY2024Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
CY2024Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2024Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92122
CY2024Q1	dei	City Area Code CityAreaCode	833
CY2024Q1	dei	Local Phone Number LocalPhoneNumber	727-2841
CY2024Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2024Q1	dei	Trading Symbol TradingSymbol	BIOR
CY2024Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2024Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2024Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2024Q1	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	35883843
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10820000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	15211000
CY2024Q1	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	822000
CY2023Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	830000
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2429000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3030000
CY2024Q1	us-gaap	Assets Current AssetsCurrent	14071000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	19071000
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1136000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1156000
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1418000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1614000
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	293000
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3302000
CY2024Q1	us-gaap	Goodwill Goodwill	6072000
CY2023Q4	us-gaap	Goodwill Goodwill	6072000
CY2024Q1	us-gaap	Assets Assets	22990000
CY2023Q4	us-gaap	Assets Assets	31215000
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	4936000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2843000
CY2024Q1	bior	Accrued Expenses And Other Liabilities Current AccruedExpensesAndOtherLiabilitiesCurrent	16984000
CY2023Q4	bior	Accrued Expenses And Other Liabilities Current AccruedExpensesAndOtherLiabilitiesCurrent	17319000
CY2024Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	27208000
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	40834000
CY2024Q1	bior	Related Party Senior Secured Convertible Notes Current RelatedPartySeniorSecuredConvertibleNotesCurrent	1976000
CY2023Q4	bior	Related Party Senior Secured Convertible Notes Current RelatedPartySeniorSecuredConvertibleNotesCurrent	1976000
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	51104000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	62972000
CY2024Q1	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	4497000
CY2023Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	9966000
CY2024Q1	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	18709000
CY2023Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	14591000
CY2024Q1	bior	Related Party Senior Secured Convertible Notes Non Current RelatedPartySeniorSecuredConvertibleNotesNonCurrent	20072000
CY2023Q4	bior	Related Party Senior Secured Convertible Notes Non Current RelatedPartySeniorSecuredConvertibleNotesNonCurrent	19179000
CY2024Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	26210000
CY2023Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	22899000
CY2024Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2583000
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3029000
CY2024Q1	us-gaap	Liabilities Liabilities	123175000
CY2023Q4	us-gaap	Liabilities Liabilities	132636000
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	164000000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	164000000
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	31166719
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	28574918
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	30429295
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	27837563
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	28000
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	25000
CY2024Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	874013000
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	868591000
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-955147000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-950958000
CY2024Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	737424
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	737355
CY2024Q1	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	19079000
CY2023Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	19079000
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-100185000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-101421000
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	22990000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	31215000
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	542000
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2000
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7005000
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7190000
CY2024Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	9053000
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	8356000
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	16058000
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	15546000
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-15516000
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-15544000
CY2024Q1	us-gaap	Interest Expense InterestExpense	2757000
CY2023Q1	us-gaap	Interest Expense InterestExpense	2680000
CY2024Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-13915000
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-864000
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	217000
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-81000
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4141000
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-17441000
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	48000
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-4189000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-17441000
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.14
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.14
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.59
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.59
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29296767
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29296767
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10970583
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	10970583
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-101421000
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2824000
CY2024Q1	bior	Stock Issued During Period Value Purchase Warrants StockIssuedDuringPeriodValuePurchaseWarrants	1062000
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1539000
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-4189000
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-100185000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-102287000
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	12524000
CY2023Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	-178000
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2384000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-17441000
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-104998000
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-4189000
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-17441000
CY2024Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	105000
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	147000
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1539000
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2384000
CY2024Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-185000
CY2023Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2024Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1939000
CY2023Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	374000
CY2024Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-10000
CY2023Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-9000
CY2024Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0
CY2023Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	100000
CY2024Q1	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-418000
CY2023Q1	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	0
CY2024Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-13915000
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-864000
CY2024Q1	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-8000
CY2023Q1	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	0
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-728000
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-772000
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1806000
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-184000
CY2024Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-83000
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	3057000
CY2024Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-211000
CY2023Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-452000
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12496000
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12098000
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	15000
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	16000
CY2024Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	20000
CY2023Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	10000
CY2024Q1	us-gaap	Proceeds From Sale Of Equity Securities Fv Ni ProceedsFromSaleOfEquitySecuritiesFvNi	3000000
CY2023Q1	us-gaap	Proceeds From Sale Of Equity Securities Fv Ni ProceedsFromSaleOfEquitySecuritiesFvNi	0
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	3005000
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-6000
CY2024Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2800000
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	12883000
CY2024Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	2813000
CY2023Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0
CY2024Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	70000
CY2023Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	359000
CY2024Q1	bior	Payments For Insurance Financing PaymentsForInsuranceFinancing	443000
CY2023Q1	bior	Payments For Insurance Financing PaymentsForInsuranceFinancing	443000
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5100000
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	12081000
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-4391000
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-23000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	15211000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	30486000
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10820000
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	30463000
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet	78000
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	0
CY2024Q1	bior	Exchange Of Convertible Notes For Senior Secured Convertible Notes And Warrants ExchangeOfConvertibleNotesForSeniorSecuredConvertibleNotesAndWarrants	5625000
CY2023Q1	bior	Exchange Of Convertible Notes For Senior Secured Convertible Notes And Warrants ExchangeOfConvertibleNotesForSeniorSecuredConvertibleNotesAndWarrants	0
CY2024Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0
CY2023Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1133000
CY2024Q1	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	314000
CY2023Q1	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	0
CY2024Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	107000
CY2023Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10600000
CY2024Q1	us-gaap	Restricted Cash RestrictedCash	200000
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-955100000
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-4200000
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12500000
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-indent:4.533%;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates include the valuation of stock options, the valuation of goodwill, the valuation of the derivative liabilities associated with the 2028 Convertible Notes, accrual for reimbursement claims and settlements, the valuation of warrant liabilities, assessing future tax exposure and the realization of deferred tax assets, and the useful lives and the recoverability of property and equipment. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities and recorded revenues and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and assumptions.</span></p>
CY2024Q1	bior	Restricted Cash Collateral For Credit Cards RestrictedCashCollateralForCreditCards	200000
CY2023Q4	bior	Restricted Cash Collateral For Credit Cards RestrictedCashCollateralForCreditCards	200000
CY2023Q4	us-gaap	Proceeds From Sale Of Property Held For Sale ProceedsFromSaleOfPropertyHeldForSale	2800000
CY2023Q4	bior	Cost Incurred In Sale Of Property Plant And Equipment CostIncurredInSaleOfPropertyPlantAndEquipment	200000
CY2024Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2260000
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2443000
CY2024Q1	us-gaap	Other Assets Current OtherAssetsCurrent	169000
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	587000
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2429000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3030000
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3319000
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3263000
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2183000
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2107000
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1136000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1156000
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	100000
CY2024Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	100000
CY2024Q1	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	293000
CY2023Q4	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	302000
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	293000
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3302000
CY2024Q1	bior	Accrual For Reimbursement Claims And Settlements Current AccrualForReimbursementClaimsAndSettlementsCurrent	3572000
CY2023Q4	bior	Accrual For Reimbursement Claims And Settlements Current AccrualForReimbursementClaimsAndSettlementsCurrent	6337000
CY2024Q1	bior	Commission And Bonus Current CommissionAndBonusCurrent	3146000
CY2023Q4	bior	Commission And Bonus Current CommissionAndBonusCurrent	2469000
CY2024Q1	bior	Vacation And Payroll Benefits Current VacationAndPayrollBenefitsCurrent	1442000
CY2023Q4	bior	Vacation And Payroll Benefits Current VacationAndPayrollBenefitsCurrent	1367000
CY2024Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	4123000
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2914000
CY2024Q1	bior	Accrued Interest Current AccruedInterestCurrent	1058000
CY2023Q4	bior	Accrued Interest Current AccruedInterestCurrent	173000
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	920000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	896000
CY2024Q1	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	606000
CY2023Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	401000
CY2024Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	542000
CY2024Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2117000
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2220000
CY2024Q1	bior	Accrued Expenses And Other Liabilities Current AccruedExpensesAndOtherLiabilitiesCurrent	16984000
CY2023Q4	bior	Accrued Expenses And Other Liabilities Current AccruedExpensesAndOtherLiabilitiesCurrent	17319000
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	583000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	818000
CY2024Q1	us-gaap	Other Sundry Liabilities Noncurrent OtherSundryLiabilitiesNoncurrent	2000000
CY2023Q4	us-gaap	Other Sundry Liabilities Noncurrent OtherSundryLiabilitiesNoncurrent	2211000
CY2024Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2583000
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3029000
CY2024Q1	bior	Fair Value Assets Level2 To Level1 Transfers Amount1 FairValueAssetsLevel2ToLevel1TransfersAmount1	0
CY2023Q1	bior	Fair Value Assets Level2 To Level1 Transfers Amount1 FairValueAssetsLevel2ToLevel1TransfersAmount1	0
CY2024Q1	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	18709000
CY2024Q1	bior	Related Party Senior Secured Convertible Notes RelatedPartySeniorSecuredConvertibleNotes	22048000
CY2024Q1	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	4497000
CY2023Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	14591000
CY2023Q4	bior	Related Party Senior Secured Convertible Notes RelatedPartySeniorSecuredConvertibleNotes	21155000
CY2023Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	9966000
CY2023Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	50000000
	bior	Class Of Warrant Or Right Period For Warrants Or Rights Exercisable ClassOfWarrantOrRightPeriodForWarrantsOrRightsExercisable	after September 18, 2023 until September 18, 2026
CY2023Q3	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	53200000
CY2023Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	35100000
CY2023	us-gaap	Gains Losses On Restructuring Of Debt GainsLossesOnRestructuringOfDebt	25500000
CY2023	bior	Troubled Debt Restructuring Debtor Future Interest Payments Capitalized TroubledDebtRestructuringDebtorFutureInterestPaymentsCapitalized	11700000
CY2024Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	300000
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	400000
CY2024Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	235000
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	384000
CY2024Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y6M
CY2024Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.096
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.094
CY2024Q1	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	771000
CY2024Q1	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	590000
CY2024Q1	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	264000
CY2024Q1	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	18000
CY2024Q1	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	0
CY2024Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	1643000
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	140000
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	1503000
CY2020Q3	bior	Number Of States Participating In Settlement NumberOfStatesParticipatingInSettlement	45
CY2023Q1	us-gaap	Payments For Legal Settlements PaymentsForLegalSettlements	0
CY2024Q1	us-gaap	Payments For Legal Settlements PaymentsForLegalSettlements	2800000
CY2024Q1	bior	Payor Recoupment PayorRecoupment	1100000
CY2020Q4	bior	Number Of Actions Pending NumberOfActionsPending	2
CY2020Q4	bior	Number Of Actions Pending NumberOfActionsPending	2
CY2024Q1	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	1000000
CY2023Q1	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	On January 3, 2023, the Company effected the Reverse Stock Split of the Company's common stock.
CY2023Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	5.3
CY2023Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	3018868
CY2023Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	5.05
CY2023Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	7300000
CY2023Q2	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	8000000
CY2023Q2	bior	Gain Loss On Warrant Liability GainLossOnWarrantLiability	1000000
CY2023Q2	bior	Warrants And Common Stock Issuance Cost WarrantsAndCommonStockIssuanceCost	700000
CY2023Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1000000
CY2023Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	4278074
CY2023Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.93
CY2023Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.87
CY2023Q4	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	9900000
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	6700000
CY2023Q4	bior	Gain Loss On Warrant Liability GainLossOnWarrantLiability	6700000
CY2024Q1	bior	Gain Loss On Warrant Liability GainLossOnWarrantLiability	1500000
CY2024Q2	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	5500000
CY2024Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	51178041
CY2022Q4	bior	Number Of Vote Per Preferred Stock Held NumberOfVotePerPreferredStockHeld	3000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	763012
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	36.23
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3200
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.12
CY2024Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1689
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	36.79
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	764523
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	36.09
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y8M12D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	764523
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	36.09
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y8M12D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	0
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	299736
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	64.14
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P7Y1M6D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	0
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.043
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.036
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.954
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.013
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.023
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M18D
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M18D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.89
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.8
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1539000
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2384000
CY2024Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	5700000
CY2024Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y3M18D
CY2024Q1	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0
CY2023Q1	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	87701608
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5672757
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0000950170-24-060530-index-headers.html	Edgar Link	pending
0000950170-24-060530-index.html	Edgar Link	pending
0000950170-24-060530.txt	Edgar Link	pending
0000950170-24-060530-xbrl.zip	Edgar Link	pending
bior-20240331.htm	Edgar Link	pending
bior-20240331.xsd	Edgar Link	pending
bior-ex31_1.htm	Edgar Link	pending
bior-ex31_2.htm	Edgar Link	pending
bior-ex32_1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
bior-20240331_htm.xml	Edgar Link	completed
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BIORQ
BIORA THERAPEUTICS, INC. Stock $biorq

2024 Q2 Form 10-Q Financial Statement

#000095017024060530 Filed on May 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BIORQ BIORA THERAPEUTICS, INC. Stock $biorq

2024 Q2 Form 10-Q Financial Statement

#000095017024060530 Filed on May 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BIORQ
BIORA THERAPEUTICS, INC. Stock $biorq